Publication
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Authors not recorded
Science2004PMID 15118125stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugGefitinibcivic_curation1.00
- geneEGFRcivic_curation1.00
- variantEGFR G719Scivic_curation1.00
- variantEGFR L858Rcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 15118125
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGFR G719S1 | ||||||||
| Gefitinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID274Gefinitib has been shown to be effective in treating cell lines with G719S missense mutations. PMID 15118125 · Paez et al., 2004 · Open in CIViC | civic |
| EGFR L858R1 | ||||||||
| Gefitinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID276Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations. PMID 15118125 · Paez et al., 2004 · Open in CIViC | civic |